Nimodipine is a Ca2 channel blocker that inhibits smooth muscle contraction and relieves vascular spasm by preventing Ca2 from entering cells. It has a strong effect on cerebral arteries, dilates cerebral blood vessels, increases cerebral blood flow, reduces ischemic brain damage, and protects and promotes memory and intellectual recovery.

This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes. Its mechanism includes increasing the sensitivity of peripheral tissues to insulin, increasing the utilization of glucose by non-insulin-dependent tissues, inhibiting hepatic gluconeogenesis, and inhibiting the uptake of glucose by intestinal wall cells. It has no obvious hypoglycemic effect on normal people and generally does not cause hypoglycemia when used alone.